MAP2K7 and neoplasm: Recently a different MEK inhibitor, selumetinib, demonstrated tumor shrinkage and clinical benefit for children with plexiform neurofibromas shrinkage [86], and has now received FDA and EMA approval for use in pediatric NF1 patients.